The U.S. POINTER trial, a two-year randomized controlled study of 2,100 adults aged 60-79 at elevated cognitive risk, demonstrates that structured multidomain interventions outperform self-guided efforts in reducing deficit accumulation frailty—a validated biomarker of biological aging. Published in The Journals of Gerontology: Series A (Espeland et al., 2026), this large-scale RCT (sample n=2,111) with low attrition and intention-to-treat analysis strengthens causal inference over prior observational cohorts. While both arms improved, the coached group—emphasizing supervised exercise, MIND-style nutrition, cognitive training, and social engagement—achieved superior frailty score reductions, aligning with the editorial lens that scalable non-pharmaceutical programs can measurably slow aging processes. Original MedicalXpress coverage understates that frailty gains did not statistically mediate cognitive benefits, implying parallel pathways such as reduced inflammation and vascular integrity not captured by the frailty index alone. Synthesizing with the foundational FINGER trial (Ngandu et al., Lancet 2015, n=1,260) reveals consistent effect sizes across populations, yet POINTER extends generalizability to U.S. demographics. A 2023 meta-analysis in Ageing Research Reviews (de Souto Barreto et al., 42 studies) further contextualizes these findings, noting minimal conflicts of interest in publicly funded trials like POINTER versus industry-sponsored drug studies. What coverage missed is the policy implication: structured programs offer cost-effective longevity infrastructure amid rising healthcare burdens, addressing root multimorbidity rather than isolated symptoms.